JanOne Inc.

JanOne Inc. is a clinical-stage biopharmaceutical company that focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. The company operates through three segments: Biotechnology, Recycling, and Technology. JanOne Inc.’s lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. Additionally, the company provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs and designs, develops, and sells cellular transceiver modules and associated wireless services.

JanOne Inc. was founded in 1976, under the name Appliance Recycling Centers of America, Inc., and is headquartered in Las Vegas, Nevada. The company changed its name to JanOne Inc. in September 2019. JanOne Inc. has a portfolio of products and services that are designed to meet the needs of both medical professionals and patients. The company’s products range from pharmaceuticals and medical devices to technology and recycling services. JanOne Inc. has established partnerships with major medical institutions and pharmaceutical companies in order to develop and commercialize its products. The company has also established research collaborations with leading universities and research centers in order to further its research and development efforts. In addition, JanOne Inc. is actively engaged in clinical trials for its products in order to demonstrate their safety and efficacy.